83 related articles for article (PubMed ID: 19303535)
1. [How can an effective drug to treat irritable bowel syndrome be successfully developed?].
Duracinsky M; Chassany O
Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S26-34. PubMed ID: 19303535
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
[TBL] [Abstract][Full Text] [Related]
7. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design.
Trentacosti AM; He R; Burke LB; Griebel D; Kennedy DL
Am J Gastroenterol; 2010 Apr; 105(4):731-5. PubMed ID: 20372121
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
Cremonini F; Talley NJ
Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
[TBL] [Abstract][Full Text] [Related]
9. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
[TBL] [Abstract][Full Text] [Related]
11. Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists.
Mangel AW; Fehnel SE
Neurogastroenterol Motil; 2008 Oct; 20(10):1086-93. PubMed ID: 18826559
[TBL] [Abstract][Full Text] [Related]
12. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain.
Williams RE; Hartmann KE; Sandler RS; Miller WC; Savitz LA; Steege JF
Am J Obstet Gynecol; 2005 Mar; 192(3):761-7. PubMed ID: 15746669
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.
Brennan BP; Fogarty KV; Roberts JL; Reynolds KA; Pope HG; Hudson JI
Hum Psychopharmacol; 2009 Jul; 24(5):423-8. PubMed ID: 19548294
[TBL] [Abstract][Full Text] [Related]
15. Definition and classification of irritable bowel syndrome: current consensus and controversies.
Longstreth GF
Gastroenterol Clin North Am; 2005 Jun; 34(2):173-87. PubMed ID: 15862928
[TBL] [Abstract][Full Text] [Related]
16. [Irritable bowel syndrome: epidemiology/economic burden].
Dapoigny M
Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S3-8. PubMed ID: 19303536
[TBL] [Abstract][Full Text] [Related]
17. Multidimensionality of symptom complexes in irritable bowel syndrome and other functional gastrointestinal disorders.
Alpers DH
J Psychosom Res; 2008 Jun; 64(6):567-72. PubMed ID: 18501256
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo.
Enck P; Zimmermann K; Menke G; Klosterhalfen S
Z Gastroenterol; 2009 Feb; 47(2):209-14. PubMed ID: 19197823
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
20. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation.
Lee V; Guthrie E; Robinson A; Kennedy A; Tomenson B; Rogers A; Thompson D
J Psychosom Res; 2008 Feb; 64(2):129-38. PubMed ID: 18222126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
